Barclays PLC Has $6.74 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV)

Barclays PLC grew its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 24.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 569,892 shares of the company's stock after purchasing an additional 110,371 shares during the period. Barclays PLC owned about 0.08% of Roivant Sciences worth $6,742,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the stock. Norges Bank acquired a new stake in Roivant Sciences during the fourth quarter valued at $52,443,000. Invesco Ltd. raised its position in Roivant Sciences by 49.7% during the fourth quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock valued at $112,563,000 after acquiring an additional 3,159,603 shares in the last quarter. Vanguard Group Inc. lifted its stake in Roivant Sciences by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock valued at $521,553,000 after acquiring an additional 2,404,232 shares during the last quarter. Pertento Partners LLP raised its holdings in shares of Roivant Sciences by 22.8% during the 4th quarter. Pertento Partners LLP now owns 3,484,918 shares of the company's stock valued at $41,227,000 after purchasing an additional 646,865 shares in the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Roivant Sciences by 17.4% in the 4th quarter. Bank of New York Mellon Corp now owns 3,439,540 shares of the company's stock valued at $40,690,000 after purchasing an additional 510,398 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company's stock.

Roivant Sciences Stock Up 1.6 %

NASDAQ ROIV traded up $0.18 during trading on Monday, hitting $11.19. The company's stock had a trading volume of 8,301,459 shares, compared to its average volume of 5,473,405. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $13.06. The firm has a market cap of $7.98 billion, a P/E ratio of -74.60 and a beta of 1.25. The firm has a 50 day moving average price of $10.34 and a 200 day moving average price of $11.14.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, equities analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the company's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $10.22, for a total value of $1,022,000.00. Following the completion of the transaction, the chief operating officer now owns 1,116,345 shares of the company's stock, valued at $11,409,045.90. This represents a 8.22 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CAO Rakhi Kumar sold 227,500 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the completion of the sale, the chief accounting officer now owns 163,264 shares of the company's stock, valued at $1,702,843.52. This represents a 58.22 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,395,541 shares of company stock worth $14,922,538. Company insiders own 7.90% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on ROIV. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Monday, April 21st.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.